Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015–2017 by Geebelen, Laurence et al.
Contents lists available at ScienceDirect
Ticks and Tick-borne Diseases
journal homepage: www.elsevier.com/locate/ttbdis
Combining primary care surveillance and a meta-analysis to estimate the
incidence of the clinical manifestations of Lyme borreliosis in Belgium,
2015–2017
Laurence Geebelena,b,⁎, Dieter Van Cauterena, Brecht Devleesschauwera,c, Sarah Moreelsa,
Katrien Tersagoa, Herman Van Oyena,d, Niko Speybroeckb, Tinne Lernouta
a Scientific Directorate of Epidemiology and public health, Sciensano, J. Wytsmanstraat 14, 1050, Brussels, Belgium
b Institute of Health and Society (IRSS), Université catholique de Louvain, Clos Chapelle-aux-champs 30, 1200 Woluwe-Saint-Lambert, Belgium
c Department of Veterinary Public Health and Food Safety, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
dDepartment of Public Health and Primary Care, Faculty of Medicine, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium
A R T I C L E I N F O
Keywords:
Lyme borreliosis
Incidence
Erythema migrans
Clinical manifestations
Systematic review
Belgium
A B S T R A C T
Lyme borreliosis (LB) is an important tick-borne disease which can cause a broad range of symptoms mainly
affecting the skin, the nervous system and the joints. This study aims to estimate the incidence of the different
clinical manifestations of LB in Belgium. The incidence of erythema migrans (EM) was estimated through the
network of sentinel general practices at 97.6/100,000 inhabitants (uncertainty interval [UI] 82.0–113.0) for the
period 2015–2017. This result was used to estimate the incidence of other LB manifestations based on their
proportional distribution (ratios) to EM reported in the neighboring countries of Belgium. To estimate these
ratios, we performed a systematic review of studies published between February 1, 2008 and January 31, 2018
and pooled the results using a random effects meta-analysis. Six studies were retained in the systematic review,
and the meta-analysis estimated the occurrence ratios for Lyme neuroborreliosis/EM, Lyme arthritis/EM and
other manifestations/EM at 0.024 (95% confidence interval [CI] 0.016–0.037), 0.022 (95% CI 0.020–0.024) and
0.014 (95% CI 0.012–0.016) respectively. Applying these ratios to the EM incidence in Belgium resulted in an
incidence estimation of 2.4/100,000 inhabitants (95% UI 1.5–3.7) for Lyme neuroborreliosis, 2.1/100,000 (95%
UI 1.7–2.6) for Lyme arthritis and 1.4/100,000 (95% UI 1.1–1.7) for other less frequent manifestations. Some of
these LB manifestations, other than EM, are more severe, hence these estimates are essential to assess the health
burden and economic cost of LB which would be highly relevant for patients, healthcare providers and pol-
icymakers. As both over- and underestimation of different clinical LB manifestations remain possible due to
characteristics of the primary surveillance systems and the disease itself, future studies to validate these esti-
mates would be of great value.
1. Introduction
Lyme borreliosis (LB) is caused by bacteria of the Borrelia burgdorferi
sensu lato (s.l.) complex and is the most prevalent tick-borne disease in
Europe and North America. It is a multisystem infectious disease, which
can generate a wide range of clinical manifestations (Stanek et al.,
2012; Steere et al., 2016). An early localized infection mainly manifests
as erythema migrans (EM), a red expanding skin lesion at the site of the
tick bite. EM is the most common manifestation of LB but it is not
always present. If untreated, disseminated infection can occur in an
early or late stage of the disease, causing more severe manifestations of
which multiple EM, Lyme neuroborreliosis (LNB) and Lyme arthritis
(LA) are the most frequent ones. Other less frequent early or late
manifestations are borrelial lymphocytoma, Lyme carditis, ocular
manifestations and acrodermatitis chronica atrophicans (ACA) (Stanek
et al., 2012; Steere et al., 2016).
In order to assess the health burden and costs of LB, data on the
incidence of all the different clinical manifestations are required
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(Geebelen et al., 2017; Mihajlovic et al., 2017; van den Wijngaard et al.,
2015, 2017b). In Belgium, the incidence of consultations for an EM is
estimated through prospective studies in a network of sentinel general
practices (SGP), which are repeated over time (2003–2004, 2008–2009
and since 2015 onwards) (Vanthomme et al., 2012). In addition, a
network of sentinel laboratories weekly reports the number of positive
serological tests for B. burgdorferi s.l., while hospitals monitor the yearly
number of hospitalizations for LB (Bleyenheuft et al., 2015; Rebolledo
et al., 2017). Yet, these data do not allow an accurate estimation of the
incidence of disseminated and late LB manifestations in Belgium. This is
because clinical information is missing for the laboratory results and a
positive serology alone does not allow to distinguish between active
and past infection (Stanek et al., 2011), and the proportion of patients
that are hospitalized is unknown. Furthermore, it is difficult to compare
reported incidences between countries, due to differences in surveil-
lance methods, health care systems, case definitions, and laboratory
tests used (European Centre for Disease Prevention and Control (ECDC),
2012; Smith and Takkinen, 2006). Nevertheless, comparing the pro-
portional occurrence of the different clinical manifestations between
countries with a similar level of health care could be possible, taking
into account that different disease manifestations are associated with
different pathogenic genospecies of the B. burgdorferi s.l. complex and
that their prevalence differs geographically (Coipan et al., 2016;
Hofhuis et al., 2015b; Jahfari et al., 2017; Steere et al., 2016; Strnad
et al., 2017). In the United States, LB is predominantly caused by B.
burgdorferi sensu stricto, a genospecies preferentially associated with
LA. In Europe, at least five genospecies are known to be pathogenic,
namely Borrelia afzelii, Borrelia garinii, B. burgdorferi sensu stricto, Bor-
relia spielmanii and Borrelia bavariensis. B. afzelii and B. garinii are most
frequently detected and more often associated with ACA and LNB, re-
spectively (Coipan et al., 2016; Jahfari et al., 2017; Rudenko et al.,
2011; Stanek and Reiter, 2011; Stanek et al., 2012). Although the
prevalence of these genospecies in ticks may vary within Europe, a
recent systematic review by Strnad et al. (2017) found no significant
difference in the proportional representation of the genospecies be-
tween Western Europe (Belgium, France, Luxembourg, and the Neth-
erlands) and Central Europe (such as Germany, Austria, Switzerland)
(Strnad et al., 2017).
The main objective of this study is to estimate the incidence of the
different clinical manifestations of LB in Belgium. In a first step, the
most recent results on the incidence of EM according to the SGP net-
work are presented. Secondly, a systematic review and meta-analysis on
the proportional distribution of the different clinical manifestations of
LB in the neighboring countries of Belgium is conducted in order to
estimate the ratios of other LB manifestations to EM. Finally, the in-
cidence of LB manifestations other than EM in Belgium is estimated by a
data synthesis integrating both steps.
2. Methods
2.1. Incidence of erythema migrans
The Belgian network of SGP is a nationwide network of general
practitioner (GP) practices representative of the Belgian GPs, in which
each practice comprises one or multiple participating physicians, who
voluntarily transmit data for different health problems (Boffin et al.,
2017). Cases of EM, defined as a skin lesion (or multiple skin lesions)
that expands over a period of days to weeks, with a diameter of
minimum 5 cm, and often with partial central clearing (Centers for
Disease Control and Prevention, 2018; Stanek et al., 2011), reported by
the network between 2015–2017 were included in this study. For each
case a questionnaire is completed containing patient characteristics and
specific questions about the tick bite (if recalled), a possible
prescription of serological tests and treatment. To estimate the popu-
lation covered by the network, the number of inhabitants per active GP
(defined as having at least 500 contact patients/year based on health
insurance data) was calculated in each of the 43 districts in Belgium
and further multiplied by the number of sentinel practices (minimum
population coverage) or the number of sentinel GPs (maximum popu-
lation coverage). The average population covered by the network for
the period 2015–2017 was estimated at 147,749 inhabitants (1.3% of
the Belgian population). EM incidence estimates were generated at
national level, for the three Belgian regions – i.e., the Brussels Capital,
Flemish and Walloon Region and per province. Uncertainty in the es-
timates was quantified and propagated using 10,000 Monte Carlo si-
mulations following a uniform distribution defined by the minimum
and maximum incidence estimate (based on the maximum and
minimum population coverage estimate respectively). Results were
summarized by the mean and a 95% uncertainty interval (UI) defined as
the 2.5th and 97.5th percentile of the uncertainty distribution. All
calculations were done in R version 3.5.0 (R Core Team, 2018).
2.2. Systematic review and meta-analysis
2.2.1. Search strategy and study selection
A systematic review on the proportional occurrence of the different
clinical manifestations of LB was conducted and reported following the
PRISMA guidelines (Moher et al., 2009) (Appendix A). Literature from
Belgium and its neighboring countries was searched through PubMed
and Embase with the following search terms (in February 2018): (Lyme
disease) AND (epidemiology OR incidence OR prevalence OR clinical
manifestation*) AND (Belgium OR France OR Netherlands OR Germany
OR Luxembourg OR United Kingdom) NOT ((animals) NOT ((animals)
AND humans)). The searches included MeSH terms in PubMed and
Emtree terms in Embase as well as free text searches. The searches were
limited to publication dates between 01/02/2008 and 31/01/2018 and
to English, Dutch, French or German language. Details of the search
strategies can be found in Appendix B (Table B1). Furthermore, grey
literature, more specifically the websites of the national public health
institutes of the included countries, was searched (Appendix B, Table
B2, Robert Koch-Institut, 2009).
All manuscripts retrieved through this search strategy were first
screened based on title and abstract. Next, full texts of potentially eli-
gible papers were obtained and assessed through the use of an inclusion
criteria checklist by two authors (LG and TL) independently. Papers
were included if they fulfilled all the following criteria: (1) description
of observational study results or surveillance data from the most recent
ten years; (2) quantitative reporting on the incidence or proportional
distribution of at least the three most frequent clinical manifestations of
LB (EM, LNB and LA) with or without reporting on the other manifes-
tations; (3) covering the general LB population and (4) using case de-
finitions in line with those published by Stanek et al. (2011), as these
are used for clinical diagnosis in Europe. More specifically, EM had to
be a purely clinical diagnosis and other LB manifestations had to be
confirmed with laboratory testing. As a consequence, studies on sub-
groups (e.g. risk groups, hospitalized patients, persons with a tick bite),
case reports and laboratory-based studies only were excluded. Only
data on confirmed cases were retained.
2.2.2. Quality assessment
The quality assessment of included studies focused on adaptations
made to the European case definitions (Stanek et al., 2011), verification
of the compliance of the reported cases with the definition and other
case validation methods applied. In addition, epidemiological data
characteristics were compared and possible limitations of the studies,
provided by the authors themselves or appraised by the reviewers, were
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assessed.
2.2.3. Data extraction
For the studies that met the inclusion criteria, the following data
were extracted into a data extraction form by two authors (LG and TL)
independently: country (and region), study design, reporting entity
(who, coverage (sentinel/comprehensive) and type (voluntary/man-
datory)), inclusion period, study population, inclusion criteria, data
collection methods, total sample size and the frequency of the clinical
manifestations. Additional information on the study quality (case de-
finitions used, validity measures taken and possible limitations) was
recorded. If important data were missing or unclear, the original author
of the paper was contacted.
2.2.4. Meta-analysis
We generated pooled estimates of the ratios of LA, LNB, and “other
manifestations” of LB to the number of EM manifestations, using
random effects meta-analyses for log-transformed rates (Riley et al.,
2011). Borrelial lymphocytoma, ACA, Lyme carditis and, if available,
ocular manifestations were combined into the group of “other mani-
festations” as only very few cases were found in the different studies.
The influence of exclusion of studies based on mandatory surveillance
was explored in an alternative scenario, as differences in surveillance
methods could influence the results. All meta-analyses were performed
using the metafor package for R version 3.5.0 (R Core Team, 2018;
Viechtbauer, 2010).
2.3. Data synthesis
The result from the incidence estimation of EM through the Belgian
SGP network was combined with the results of the meta-analysis on the
proportional occurrence of clinical manifestations of LB in order to
calculate the total incidence of LB in Belgium, including disseminated
and late manifestations (Fig. 1). Uncertainty, quantified as uniform
distributions for incidence estimates and log-normal distributions for
ratios, was propagated using 10,000 Monte Carlo simulations. All cal-
culations were performed in R version 3.5.0 (R Core Team, 2018.
3. Results
3.1. Incidence of erythema migrans
In the period 2015–2017, 420 EM cases were reported by the SGP
network, resulting in an estimated annual incidence of 97.6 EM cases/
100,000 inhabitants (95% UI 82.0–113.0). The estimated annual in-
cidence corresponded to 98.0 cases/100,000 (UI 81.8–114.2) in 2015,
106.1 cases/100,000 (95% UI 90.1–122.2) in 2016 and 88.5 cases/
100,000 (95% UI 74.3–102.8) in 2017. Fig. 2 shows the annual in-
cidence for each province in Belgium. The estimated annual incidence
ranged from 30.9 cases/100,000 (95% UI 21.4–40.3) in East Flanders to
390.9/100,000 (95% UI 329.7–451.9) in Limburg. Regionally the es-
timated annual incidence was 126.0 cases/100,000 (95% UI
101.0–150.9) in the Flemish region, 74.2 cases/100,000 (95% UI
68.3–80.1) in the Walloon region and 34.0 cases/100,000 (95% UI
28.4–39.6) in the Brussels Capital region.
Women represented 49.6% of the cases and the incidence peaked in
the 60–69 years age group, especially in men (Fig. 3). A typical sea-
sonality with a peak during the summer period was also observed, with
60.5% of the cases reported between June and August.
Fig. 1. Overview of methods used to quantify the incidence of clinical mani-
festations of Lyme borreliosis.
aIncidence in Belgium.
EM: erythema migrans; LA: Lyme arthritis; LNB: Lyme neuroborreliosis; OTH:
other manifestations.
Fig. 2. Estimated annual incidence of erythema migrans (cases/100,000 inhabitants) per province, Sentinel General Practices network, Belgium, 2015–2017.
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3.2. Systematic review and meta-analysis
3.2.1. Literature search
We identified 836 citations of which, after deletion of duplicates,
710 were screened based on title and abstract. Among these, 15 were
potentially eligible epidemiological studies or reports of surveillance
data for which full texts were obtained. A total of three studies met the
inclusion criteria (Hofhuis et al., 2015b; Vandenesch et al., 2014;
Wilking and Stark, 2014). Studies were excluded based on: double re-
porting (Hofhuis et al., 2015a; van den Wijngaard et al., 2015), data
(partly) older than 2008 (Blanc, 2009; Dillon et al., 2010; Fulop and
Poggensee, 2008; Halsby et al., 2014), review article (Dubrey et al.,
2014), not reporting on EM, LA and LNB (Bleyenheuft et al., 2015; Klier
et al., 2013; Marcu et al., 2013; Vanthomme et al., 2012) and not in line
with the European case definitions (Slack et al., 2011). In addition, data
from two surveillance reports were included through the search of
public health websites of the concerned countries (Heinzinger et al.,
2017; Serre et al., 2017). Since one report described two surveillance
systems, three data sets could be added. Duplicate data were excluded.
A PRISMA flowchart is provided in Fig. 4. No studies or reports from
Luxembourg were found and none of the UK studies fulfilled the in-
clusion criteria since surveillance in the UK is based on laboratory
confirmed cases only.
3.2.2. Study characteristics
The selected data were from the Netherlands (n=1) (Hofhuis et al.,
2015b), Germany (n=3) (Heinzinger, 2016; Wilking and Stark, 2014) and
France (n=2) (Serre et al., 2017; Vandenesch et al., 2014). An overview of
study characteristics is presented in Appendix C (Table C1). LB cases were
reported by GPs at a national level in two of the studies included – i.e.,
retrospectively through a survey of GPs in the Netherlands (Hofhuis et al.,
2015b) and prospectively through weekly reporting by the Sentinelles GP
surveillance network in France (Vandenesch et al., 2014). In one area in
France, Franche-Comté (Serre et al., 2017), and one area in Germany, Ba-
varia (Lyme Disease Incidence-Study: LYDI-Sentinel) (Heinzinger et al.,
2017), cases were reported prospectively by a network of both GPs and
medical specialists. Two reports provided results from mandatory notifica-
tion systems in Germany at a regional level: for physicians and laboratories
in six eastern states (Wilking and Stark, 2014) and for physicians in Bavaria
(Heinzinger et al., 2017). The duration of the different study periods ranged
between one and four years. The total number of confirmed LB cases in-
cluded in the studies ranged from 282 to 18,894 patients. Multiple EM,
although a disseminated manifestation, was included in the group of EM
patients in all studies.
3.2.3. Quality assessment
As requested in the inclusion criteria, case definitions used in the studies
included were in line with the European case definitions (Stanek et al.,
2011), with some small modifications made (Appendix C, Table C2).
Compliance of the reported cases with the case definitions was checked in
all studies. This was done for all cases, except in the Dutch study which
validated part of their disseminated LB cases only (the results were extra-
polated to all disseminated cases). As an additional validation Hofhuis et al.
screened cases of GPs reporting the 10% highest incidence and excluded
them if clearly deviating answers or unsatisfactory internal consistency was
found (Hofhuis et al., 2015b). The French study by Vandenesch et al.
(2014), the LYDI-Sentinel study in Bavaria (Heinzinger et al., 2017) and the
study in Franche-Comté (Serre et al., 2017) examined the cases and con-
tacted physicians when necessary (e.g. missing or inconsistent data). The
Bavarian mandatory reporting screened and corrected cases, at least for the
first year, to increase data exhaustiveness. Subsequently, measures (e.g.
revision of reporting form) were undertaken to allow future data collection
without manual data correction (Binder et al., 2015). With exception of the
Dutch study, a more detailed description on the age and gender of the in-
cluded cases and a seasonality description were available in all studies. A
bimodal age distribution (peak in 5–10 year-old and in 45–70 year-old) was
observed in the studies for which these data were available. A slightly
higher percentage of females affected and a clear seasonality was reported
by all the studies (Heinzinger et al., 2017; Hofhuis et al., 2015b; Serre et al.,
2017; Vandenesch et al., 2014; Wilking and Stark, 2014). None of the
studies were excluded because of poor quality.
Fig. 3. Estimated annual incidence of erythema migrans (cases/100,000 inhabitants) by age and gender, Sentinel General Practices network, Belgium, 2015–2017.
Fig. 4. Study selection flowchart.
*One record provided data from two studies, included as two studies.
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3.2.4. Data extraction
The primary data of included studies are provided in Table 1.
3.2.5. Meta-analysis
The pooled estimates of the ratios of LNB, LA and other manifes-
tations to the number of EM manifestations are summarized in Table 2.
The results of a scenario analysis excluding the studies based on
mandatory notification are presented in Appendix D, Table D1–D3 . No
important differences were observed.
3.3. Data synthesis
Table 3 presents the estimated annual incidences of the main clin-
ical manifestations of LB in Belgium based on the annual incidence of
EM (2015–2017) and the ratios of the other manifestations to EM, es-
timated in the meta-analysis.
4. Discussion
Based on the results of the SGP network, the annual incidence of EM
in Belgium in 2015–2017 (97.6 cases/100,000 inhabitants (95% UI
82.0–113.0)) is comparable to the incidence in 2008–2009 (93.9/
100,000 (95% UI 85.0–102.9)) (as presented by Vanthomme et al.
(2012), but recalculated based on current methodology). Other data
sources also did not indicate a significant increase of LB in the Belgian
population over the past decade (Bleyenheuft et al., 2015; De
Keukeleire et al., 2017; Rebolledo et al., 2017). Although both GP-re-
lated and patient-related factors may contribute to differences in noti-
fication of EM by the SGP network in the different provinces, the ob-
served higher incidences in Limburg, Antwerp and Luxemburg are
consistent with results of laboratory surveillance of positive serology
tests and reporting of tick bites in Belgium through an online citizen-
based platform (Bleyenheuft et al., 2015; Rebolledo et al., 2017;
Sciensano, 2018). Important regional differences also exist in other
European countries (Hofhuis et al., 2016; Vandenesch et al., 2014;
Wilking and Stark, 2014).
Only six studies were found that met the inclusion criteria of the
systematic review. As expected, EM was the most prevalent manifes-
tation in all these studies. According to our meta-analysis, LNB and LA
occur in similar proportions (ratio to EM of 0.024 and 0.022 respec-
tively) and, even joined in one group, other LB manifestations are re-
latively rare (ratio of 0.014). The proportion of EM (93–97%) reported
in the six studies included in the systematic review and meta-analysis
was higher in comparison with other, often older, studies from
European countries, but these data often had their own methodological
limitations (Altpeter et al., 2013; Berglund et al., 1995; Cimmino, 1998;
Huppertz et al., 1999; Letrilliart et al., 2005; Mehnert and Krause,
2005; Mihajlovic et al., 2017; Priem et al., 2003; Rizzoli et al., 2011).
The only available data on the frequency of the different manifestations
for Belgium are reported by a study by Bigaignon et al. in 1989
(Bigaignon et al., 1989). In this study, only seropositive patients were
included, explaining the lower proportion of EM (63%), as laboratory
tests may yield negative results in this early disease stage. Likewise, a
lower proportion of EM (range 60%–91%) is seen in other studies or
surveillance reports based on laboratory criteria only and/or in hos-
pital-based studies (Dillon et al., 2010; Dryden et al., 2015; Lipsker
et al., 2001; Lovett et al., 2008; Marcu et al., 2013). Furthermore, an
increased awareness on LB in the past decades might have caused a shift
towards diagnosis and treatment in an earlier disease stage, avoiding
more disseminated and late manifestations (Wormser et al., 2006).
Therefore, only data from the most recent ten years were included in
our review. Also, the meta-analysis focused on neighboring countries
only, as we expect them to be more comparable with regard to geo-
graphical and climatic characteristics, to the prevalence of the Borrelia
species in ticks (Strnad et al., 2017) and to changes in awareness on LB.
The risk of bias in the results of the systematic review and meta-
analysis is dependent on the primary data included as these have their
individual risk of bias. This mainly consists of possible disproportionate
over- or underestimation of one of the clinical manifestations compared
to the others. This is influenced by the study design or surveillance
method of the studies included, but also by the healthcare system that is
in place in the concerned country (van den Wijngaard et al., 2017a).
Ideally, a random sample representative of all physicians diagnosing
manifestations of LB in a country (i.e. general practitioners, infectious
disease specialists, dermatologists, neurologists, rheumatologists, pe-
diatricians and cardiologists) would report the number of cases, with a
100% compliance and sufficient clinical and laboratory details to check
accordance with the case definitions. In reality, this is not available for
any country, nor feasible. The studies from France and the Netherlands
are both based on GP reporting only and might underestimate the
proportion of manifestations other than EM as these are more severe
and difficult to diagnose, and therefore more often seen by medical
specialists. Nevertheless, in both countries patients are obliged to visit a
Table 1
Absolute numbers of clinical manifestations of Lyme borreliosis in the studies
included in the systematic review and meta-analysis.
Source EMa LA LNB OTH
Hofhuis et al., 2015b
(+ personal communication)
11,442 234 198 156
Vandenesch et al., 2014 309 10 6 7b
Wilking and Stark, 2014 18,016 367 630c N/A
Heinzinger et al., 2017; Mandatory 15,797 373 302c N/A
Heinzinger et al., 2017;
LYDI
276 9 1c N/A
Serre et al., 2017 394 4 20 5
EM: erythema migrans; LA: Lyme arthritis; LNB: Lyme neuroborreliosis; OTH:
other manifestations; N/A: not available.
a Multiple erythema migrans was included in the EM group.
b This number includes all other manifestations except ocular manifesta-
tions.
c Only acute LNB was included in the study.
Table 2
Ratios of LNB, LA and other LB manifestations to EM manifestations.
Ratio 95% confidence interval
LNB EM/ 0.024 0.016–0.037
LA EM/ 0.022 0.020–0.024
OTH EM/ a 0.014 0.012–0.016
EM: erythema migrans; LNB: Lyme neuroborreliosis; LA: Lyme arthritis; OTH:
other manifestations.
aStudies without results for other manifestations (N=3) excluded from ana-
lysis.
Table 3
Estimated annual incidences and absolute numbers of cases of EM, LNB, LA and
other LB manifestations in Belgium, period 2015–2017.
Annual incidence per
100,000
95% UI Absolute number casesa +
95% UI
EM 97.6 82.0–113.0 11,022 (9267–12,768)
LNB 2.4 1.5–3.7 270 (164–418)
LA 2.1 1.7–2.6 240 (195–289)
OTH 1.4 1.1–1.7 154 (120–192)
Total LBb 103.5 86.9–119.8 11,685 (9821–13,537)
EM: erythema migrans; LNB: Lyme neuroborreliosis; LA: Lyme arthritis; OTH:
other manifestations; UI: uncertainty interval.
a Based on mid-year population Belgium, 2016 (Public Health and
Surveillance, 2017).
b Total clinical LB manifestations.
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GP before referral to a specialist and it is expected that the participating
GPs report both on cases diagnosed by themselves as on those diag-
nosed by the specialists (Hofhuis et al., 2015a, b; Vandenesch et al.,
2014). In practice this might not always be the case and there might
still be an overestimation of the proportion of EM (Vandenesch et al.,
2014). In the studies in Franche-Comté and Bavaria (LYDI-Sentinel)
both GPs and specialists are reporting cases. Nevertheless, the ratio of
other LB manifestations to EM in the study in Franche-Comté is com-
parable to the national GP study in France (Serre et al., 2017;
Vandenesch et al., 2014); in the LYDI-Sentinel study (Bavaria) the ratio
is even lower compared to the other studies. The surveillance based on
mandatory notification (two studies in Germany) has the advantage
that it is obligatory for all types of physicians (and laboratories, for the
study by Wilking and Stark, (2014)), but in practice it could be prone to
underreporting (Jones et al., 2012; Naleway et al., 2002; Schiffman
et al., 2018; van den Wijngaard et al., 2017a). It is true that LB in-
cidence in Germany has previously been estimated to be higher based
on a prospective, population-based study in the Würzburg region in
Central-Germany in 1999 (Huppertz et al., 1999). However, since only
proportions of different manifestations and not the incidences are in-
cluded in our analysis, and because of the important advantage of
participation of all types of physicians, these studies were included in
the meta-analysis. Note that underreporting may be higher for EM than
for the other manifestations as it is less severe and easy to treat
(Schiffman et al., 2018; White et al., 2018; Wilking and Stark, 2014).
Another limitation from the study by Wilking and Stark, (2014) is that
in one state, mandatory notification only applies to the laboratories
through which EM is less often diagnosed and thereby may be under-
estimated. Furthermore, it could be possible that some cases are re-
ported twice, by a physician and laboratory. Despite the heterogeneity
between the studies included in the review (different study designs)
they resulted in comparable estimations of the proportion of the clinical
manifestations. In addition, the possible impact of exclusion of the
mandatory notification data from our meta-analysis was checked
through an alternative scenario; the final ratios estimated were very
similar to the results presented (Appendix D).
Our study allowed estimating for the first time, the annual in-
cidences of other Lyme borreliosis manifestations than EM, based on
routine EM surveillance and on information from neighboring coun-
tries. Nevertheless, there are some limitations to this study. Some
concern the estimation of the EM incidence itself. The Belgian SGP
network is based on a voluntary participation of GPs who have to de-
clare cases actively. Underreporting is possible, especially in districts
less affected by LB due to lower awareness (Smith and Takkinen, 2006).
In addition, as an EM disappears after some time, and as patients may
not always be aware of the necessity of treatment, cases might not al-
ways seek medical care (=under-ascertainment). This is a common
limitation with all the studies included in the meta-analysis. Both un-
derreporting and under-ascertainment lead to underestimation, but the
exact magnitude of this problem is unknown. On the other hand, er-
roneously diagnosing other skin rashes as an EM could lead to over-
estimation (European Centre for Disease Prevention and Control
(ECDC), 2012; Hubalek, 2009; Smith and Takkinen, 2006). To improve
data quality, the SGPs receive a clinical case definition and instructions
on a yearly basis. However, no further validation of the reported cases
is carried out.
Other limitations are related to the systematic review and meta-
analysis. Firstly, as inclusion criteria were broad, differences in study
and surveillance methodologies between included data existed. A
random effects meta-analysis was used to explicitly take into account
these differences in the meta-analysis. Secondly, in three out of six in-
cluded studies, the patient sample size was rather small (Heinzinger
et al., 2017; Serre et al., 2017; Vandenesch et al., 2014). Since LB
manifestations other than EM, LNB and LA (ACA, Borrelial lymphocy-
toma, Lyme carditis and ocular manifestations) were not included in the
German studies, less data could be included in the analysis of their ratio
to EM. Furthermore, in one of the remaining studies ocular manifes-
tations were not included (Vandenesch et al., 2014). The German stu-
dies also only considered early LNB and not late LNB cases (Heinzinger
et al., 2017; Wilking and Stark, 2014). As the latter is extremely rare in
Europe (< 2-5% of all LNB), this was not adjusted for in the meta-
analysis (Koedel et al., 2015; Mygland et al., 2010). In general, we
believe that an underestimation of the proportion of LB manifestations
other than EM is possible as the included studies based on GP reporting
might be prone to underestimation of these manifestations as patients
may visit a specialist directly. Furthermore, the decision to include only
studies based on confirmed LB cases is also likely to have caused an
underestimation of these LB manifestations other than EM: as more
specific data are required for a confirmed diagnosis, including clinical
and laboratory data (serum ELISA and Western blot, cerebrospinal fluid
analysis, intrathecal antibody production, pleocytosis,…) (Stanek et al.,
2011), chances are higher that these manifestations are classified as
probable or possible due to missing information and thereby not in-
cluded in our analysis.
Finally, the incidence estimates are based on reported cases only.
The true incidences may be higher due to under-ascertainment (not all
patients seek healthcare, mainly for EM) and underreporting (for all
manifestations). Additional studies may allow assessing this under-
estimation and better estimating the exact number of the different LB
manifestations, including probable cases.
5. Conclusion
An estimation of the incidence of the different clinical manifesta-
tions of Lyme borreliosis is useful to follow-up disease trends and ne-
cessary to estimate the health burden and costs of the disease in a
country. However, collecting representative data on all the different
manifestations is very complex and time consuming. This study used
routine surveillance data of EM and data available from other (neigh-
boring) countries to estimate the incidence of other, less frequent
manifestations. Future studies to validate these estimates would be of
great value.
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